A GLP-1 agonist is a medication that mimics a natural gut hormone called glucagon-like peptide-1, which your body releases after eating to help regulate blood sugar, appetite, and digestion. These drugs were originally developed for type 2 diabetes but have become widely prescribed for weight loss and are now recognized for significant heart and kidney benefits as well.
How GLP-1 Works in Your Body
Your intestines naturally produce GLP-1 every time you eat. This hormone does three things simultaneously: it signals your pancreas to release insulin, it tells your liver to stop pumping out extra sugar by suppressing a counter-hormone called glucagon, and it slows the rate at which food leaves your stomach. That slower digestion keeps you feeling full longer and blunts the blood sugar spike that normally follows a meal.
The problem is that natural GLP-1 breaks down in about two minutes. An enzyme in your blood chops it up almost as fast as your gut releases it. GLP-1 agonist medications are engineered to resist that enzyme, so they last dramatically longer. Depending on the specific drug, the active ingredient stays in your body for hours to several days, keeping those blood sugar, appetite, and digestion effects going continuously.
Available Medications and How They’re Taken
Several GLP-1 agonists are on the market, and the biggest practical difference between them is how often you take them. Some require a daily injection, others a weekly injection, and one is available as a daily pill.
- Semaglutide is the most widely recognized. It comes as a once-weekly injection (branded for diabetes and weight loss under different names) or as a daily oral tablet. It has a half-life long enough to maintain steady levels between weekly doses.
- Liraglutide is a once-daily injection with a half-life of about 13 hours. It was one of the earliest GLP-1 drugs to show cardiovascular benefits and recently became available in a generic version, the first generic GLP-1 injection approved by the FDA.
- Dulaglutide is a once-weekly injection with a half-life of about five days.
- Exenatide comes in two forms: a twice-daily injection and a once-weekly extended-release version. A generic of the twice-daily formulation has also been approved.
- Tirzepatide is a once-weekly injection that activates both the GLP-1 receptor and a second gut hormone receptor called GIP. This dual action produces stronger effects on blood sugar and body weight than GLP-1-only drugs.
All injectable forms use a small prefilled pen with a short, thin needle injected under the skin of the abdomen, thigh, or upper arm. Most people rotate injection sites weekly.
Blood Sugar Control in Type 2 Diabetes
GLP-1 agonists typically lower HbA1c (a three-month average of blood sugar) by 1% to 1.5%, though the range across studies runs from 0.5% to 1.8% depending on the specific medication and the patient’s starting level. For context, dropping HbA1c by even 1% substantially reduces the risk of diabetes-related complications like nerve damage, kidney disease, and vision loss.
One feature that makes these drugs appealing compared to older diabetes medications is that they carry a very low risk of causing dangerously low blood sugar. Because they stimulate insulin release only when blood sugar is elevated, they essentially have a built-in safety brake. This glucose-dependent mechanism is a meaningful advantage over insulin or certain oral diabetes pills that can push blood sugar too low.
Weight Loss Effects
The appetite-suppressing and digestion-slowing effects of GLP-1 agonists produce significant weight loss, which is why these drugs have been approved specifically for obesity treatment in people without diabetes. In clinical trials, semaglutide at the weight-management dose produced an average weight loss of about 15% of body weight over 68 weeks. Tirzepatide produced even larger results: 15% at the lowest dose and nearly 21% at the highest dose over 72 weeks.
To put that in real numbers, a person starting at 250 pounds could expect to lose roughly 37 to 52 pounds over about a year and a half, depending on the medication and dose. These results are far beyond what older weight-loss drugs achieved and approach the range previously seen only with bariatric surgery. The weight loss is not purely cosmetic. It drives improvements in blood pressure, cholesterol, joint pain, sleep apnea, and liver fat.
In late 2025, the World Health Organization issued its first guideline recognizing GLP-1 therapies as a long-term treatment for obesity as a chronic disease. The WHO recommends combining these medications with structured behavioral programs that include diet and physical activity changes.
Heart and Kidney Benefits
Beyond blood sugar and weight, GLP-1 agonists reduce the risk of serious cardiovascular events. A meta-analysis of 13 large trials involving over 83,000 patients found that these drugs lowered the risk of major cardiovascular events (heart attack, stroke, or cardiovascular death) by 14%. All-cause mortality dropped by 13%, and stroke risk fell by 13% to 26% depending on whether the stroke was fatal or nonfatal.
These benefits held up across different patient groups: men and women, people with and without existing heart disease, and people with varying levels of kidney function. Kidney outcomes also improved, with a 24% reduction in a composite measure of kidney disease progression. Researchers have noted that the cardiovascular benefits extend beyond what weight loss alone would explain, suggesting the drugs have direct protective effects on blood vessels and the heart.
Common Side Effects
Gastrointestinal symptoms are the most frequent issue. Across studies, nausea affects roughly a third of patients and is the number one reason people consider stopping. Diarrhea occurs in about 20% of patients, and vomiting in about 16%. These side effects are usually worst during the first few weeks or after a dose increase, which is why doctors start at a low dose and gradually titrate up over several weeks or months.
For most people, the nausea fades as the body adjusts. Eating smaller meals, avoiding high-fat foods, and staying hydrated can help during the adjustment period. Less commonly, GLP-1 agonists can trigger pancreatitis (inflammation of the pancreas) or gallbladder problems, which would require stopping the medication.
Who Should Not Take Them
GLP-1 agonists carry a boxed warning related to thyroid cancer. In animal studies, these drugs stimulated growth of a specific type of thyroid cell, raising concern about medullary thyroid carcinoma. While this hasn’t been confirmed in humans, anyone with a personal or family history of medullary thyroid cancer or a related genetic condition called Multiple Endocrine Neoplasia syndrome type 2 should not use these medications. Doctors typically review thyroid history and may order imaging before starting treatment.
Pregnant women should not take GLP-1 agonists. People with a history of severe pancreatitis also need to discuss risks carefully, since these drugs can occasionally trigger pancreatic inflammation.
Why These Drugs Differ From Older Options
The shift GLP-1 agonists represent in treating both diabetes and obesity is significant. Older diabetes medications primarily targeted blood sugar without meaningful effects on weight, heart disease, or kidney function. Many caused weight gain. GLP-1 agonists address multiple problems simultaneously: they lower blood sugar, reduce body weight, protect the cardiovascular system, and slow kidney disease progression. That combination of benefits, along with once-weekly dosing convenience, explains why prescriptions for this drug class have surged and why generic versions are now entering the market to improve access.